Real-world data shows growing blood-based Alzheimer’s testing and rising Medicare payments. Read the full announcement →

ALZpath Reports Real-World Data Showing Growing Utilization of Blood-Based Alzheimer’s Testing and Rising Medicare Payments

Analysis Presented at CTAD Finds Rising Testing Volume and Average Payments, with Nearly 78% of Medicare Part B Claims for Phosphorylated Tau (pTau) Testing Receiving Payment

CARLSBAD, Calif., Nov. 16, 2026, ALZpath, Inc., a leader in blood test-based diagnostic solutions for Alzheimer’s disease, today announced findings from a real-world analysis showing growing utilization of phosphorylated tau (p-tau) testing under traditional Medicare Part B. The analysis, covering January 2025 through April 2026, found increasing testing volume and rising average payments, providing insight into real-world utilization and reimbursement patterns as blood-based biomarkers become an increasingly important part of the Alzheimer’s diagnostic landscape.

The findings will be presented at the Clinical Trials on Alzheimer’s Disease (CTAD) conference in Boston, Massachusetts on Thursday, November 19, from 12:05-1:05 p.m.

Key findings include:

  • Testing volume increased sharply in 2026: Monthly claims rose from 5,379 in December 2025 to 11,516 in January 2026, reaching 12,623 in April.
  • 77.5% of claims received payment: Of 95,900 unique claims for phosphorylated tau testing, more than three-quarters received a nonzero Medicare payment.
  • Average payments increased: The mean payment per paid claim rose from $43 in 2025 to $125 during January through April 2026, approaching the 2026 Clinical Laboratory Fee Schedule amount of $128.
  • Medicare payments exceeded $6.3 million: Total payments for the claims analyzed reached $6,336,866.

“These findings provide an important real-world view of how blood-based Alzheimer’s testing is being used and reimbursed under Medicare,” said Mike Banville, Chief Executive Officer of ALZpath. “While the data show that reimbursement is already occurring in a substantial proportion of cases, establishing clear and consistent coverage policies will be critical as these tests become more widely used in clinical practice.”

The study, conducted using the LumaClaims database, analyzed claims submitted under CPT code 84393, which covers phosphorylated tau testing in plasma and cerebrospinal fluid (CSF). Based on an analysis of other codes associated with CPT 84393, only a small fraction of claims are likely to represent CSF testing. A subset analysis of 42,380 claims that included an associated venipuncture CPT code found reimbursement rates and amounts similar to those observed in the full dataset.

“Real-world claims data offer a baseline for understanding the adoption and reimbursement of emerging diagnostic technologies beyond controlled research settings,” said Soeren Mattke, Director of The USC Brain Health Observatory at University of Southern California and co-author of the study. “These findings provide an important initial benchmark for tracking pTau testing utilization and coverage under traditional Medicare as new testing options become available.”

The majority of claims were associated with laboratory-developed tests (LDTs). The authors note that further research is needed to assess utilization and reimbursement as FDA-cleared in vitro diagnostic (IVD) tests become more widely available.

About ALZpath

ALZpath, Inc. is a leader in blood test-based diagnostic solutions for Alzheimer’s disease. Its proprietary pTau217 antibody, used in many of the most advanced and widely available blood-based tests, is helping transform how Alzheimer’s disease is detected, treated, and monitored. Through licensing agreements with global industry leaders and collaborations with world-class laboratories, ALZpath enables partners to deliver accurate, scalable testing to clinicians and patients worldwide. The company’s innovations have earned numerous industry honors, including Time Magazine Best Inventions (2024), Fast Company Most Innovative Companies (2025) and BioTech Breakthrough “Diagnostic Innovation of the Year” (2025).

To learn more, visit https://alzpath.bio/ and follow ALZpath on LinkedIn, X, BlueSky, and Facebook .

ALZpath Media Contact

Jessica Hoffman
FINN Partners
Jessica.hoffman@finnpartners.com 

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on ALZpath’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause ALZpath’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in ALZpath’s filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” sections contained therein. Except as required by law, ALZpath assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.